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Experimental autoimmune encephalomyelitis in the
common marmoset, a nonhuman primate species
(Callithrix jacchus), is a new model for multiple scle-
rosis. Given the close immunological relationship be-
tween marmosets and humans, it is an attractive
model for investigating immunopathological path-
ways relevant to multiple sclerosis and to evaluate
new treatments for the disease. Unlike in the origi-
nally documented model, experimental autoimmune
encephalomyelitis induced without the use of Borde-
tella pertussis led to a chronic disease of moderate
severity. The clinical course of experimental autoim-
mune encephalomyelitis in the present model was
mainly chronic and progressive, but periods of in-
complete remission did occur. At the chronic stage of
the disease, actively demyelinating lesions were
found together with inactive demyelinated and remy-
elinated (shadow) plaques. Before immunization and
during clinically active experimental autoimmune en-
cephalomyelitis, T1- and T2-weighted magnetic reso-
nance brain images were obtained. Correlation of the
data from the magnetic resonance images and the
neuropathology analysis revealed that the hyperin-
tense regions in T2-weighted images represented both
active and inactive remyelinating lesions. Quantifica-
tion showed that the number of lesions in T2-
weighted magnetic resonance images equalled those
found by pathological examination, and thus T2-
weighted magnetic resonance imaging can be used to
discern the total lesion load. Extravasation of gado-
linium-diethylenetriamine-penta-acetic acid (triple
dose) was found only in lesions, which by histopathol-
ogy were shown to be engaged in the process of active
demyelination. (Am J Pathol 1998, 153:649–663)
Multiple sclerosis (MS) is a chronic inflammatory and
demyelinating disease of the central nervous system
(CNS). Although there is a large variability among indi-
vidual patients, MS typically follows a chronic-progres-
sive or relapsing-remitting course. In the latter case, dis-
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ease episodes with neurological abnormalities (relapse/
exacerbation) alternate with periods of partial or
complete recovery (remission). The typical histopatho-
logical hallmark of MS is the presence of inflammatory,
demyelinating lesions within the CNS. Most of these le-
sions contain mononuclear cells such as lymphocytes
and macrophages, whereas granulocytes are not typi-
cally found. Demyelinated lesions are found throughout
the CNS in a perivascular or periventricular location.1
Magnetic resonance imaging (MRI) is presently the
diagnostic imaging modality of choice in MS.2–4 T2-
weighted sequences are especially sensitive to structural
alterations of CNS tissue. All lesion stages, from early
inflammation to late chronic stages, are visualized as
hyperintense regions. Therefore, T2-weighted MRI is usu-
ally applied to assess the spatial distribution of plaques
and to determine the total lesion load.5 Active lesions can
be distinguished from inactive ones by increased perme-
ability of the blood-brain barrier (BBB) for intravenously
injected gadolinium. This results in local enhancement of
the signal intensity of T1-weighted images. Lesions with
contrast-induced regional signal enhancement correlate
well with disease activity both in MS6–9 and in the exper-
imental model experimental autoimmune encephalomy-
elitis (EAE).10 However, limited information is available on
pathological characteristics of MRI-detectable lesions.
The objectives of this study were to investigate the
histopathological basis of MRI-detectable lesions in the
EAE model in marmoset monkeys. The obvious advan-
tage of any EAE model is that MR images can be re-
corded before and at defined time points after disease
onset. When regions of interest appear in MRI, animals
can be sacrificed immediately after in vivo MRI analysis to
characterize regions of interest by immunohistopatho-
logical techniques. The EAE model in marmosets is of
particular interest in view of the close similarity between
the human and marmoset immune systems.11–15
The present study shows that the development of le-
sions in the marmoset brain white matter can be very well
visualized with MRI techniques similar to those used for
diagnosis of MS. Moreover, for histopathological charac-
terization of MRI-detectable lesions, the same reagents
could be used as those applied for the stage character-
ization of lesions in the CNS of MS patients. Our present
pathological investigation reveals the presence of both
active and inactive, as well as remyelinating, plaques in
the CNS of EAE-affected marmosets that strongly resem-
ble the plaques in the CNS of MS patients. Correlation of
MRI and pathology revealed that the number of lesions in
tissue sections equalled those found by T2-weighted
MRI. Furthermore, none of the pathologically defined in-
active lesions displayed gadolinium enhancement.
Nearly all lesions that did show gadolinium enhancement
of the T1-weighted nuclear magnetic resonance (NMR)
signal could be classified as early active. In summary, we
demonstrate here that the present EAE model resembles
MS not only in its clinical expression, but also in radio-
logical and histopathological aspects of the lesions that
are found in the CNS white matter.
Materials and Methods
Monkeys
Eleven marmosets (Callithrix jacchus) were used for this
study. The sex and birth dates (month/year) of the mon-
keys were: EB: male, 4/1992; EC: male, 8/1990; ED:
female, 6/1992; EE: male, 4/1992; EG: female, 8/1992;
EH: male, 6/1992; EI: male, 8/1992; EJ: male, 4/1993; EK:
male, 4/1993; EL: male, 4/1993; and GY: male, 7/1994.
The body weight of the monkeys at the start of the exper-
iment ranged between 295 and 320 g. The monkeys were
bred and raised at the Biomedical Primate Research
Centre (Rijswijk, The Netherlands). Marmosets of either
sex can be used, because there is no sex-linked differ-
ence in susceptibility to EAE. During the experiments, the
monkeys were individually housed in spacious cages
with padded shelter on the bottom. The daily diet con-
sisted of commercial food pellets for nonhuman primates
(Hope Farms, Woerden, The Netherlands), supple-
mented with rice and fresh fruit. Drinking water was pro-
vided ad libitum.
EAE Induction
Myelin was isolated as described16 from human brain
white matter, which was kindly provided by Dr. Rivka
Ravid of the Dutch Brain Bank (Amsterdam, The Nether-
lands). The myelin concentration in the stock solution was
30 mg/ml on a dry-weight basis and 1.3 mg/ml protein on
a protein basis as measured according to Bradford.17
In a first group of five monkeys (EB, EC, ED, EE, and
EG), EAE was induced essentially as described earli-
er.18,19 The myelin stock solution was emulsified in an
equal volume of enriched complete adjuvant. Enriched
complete adjuvant was prepared by mixing incomplete
adjuvant (DIFCO Laboratories, Detroit, MI) with 6 mg/ml
desiccated mycobacteria (Mycobacterium tuberculosis,
H37A, DIFCO) followed by brief sonication. Under ket-
amine anesthesia, each monkey was injected intrader-
mally on the back with 600 l of emulsion divided over
four spots, two in the inguinal and two in the axillary
region. In addition, 1 ml phosphate-buffered saline (pH
7.4) containing 1010 heat-inactivated B. pertussis parti-
cles was injected immediately after immunization and 48
hours later.
In a second group of six monkeys, the original immu-
nization protocol was modified in two respects. First, the
Mycobacterium concentration in the antigen-adjuvant
emulsion was reduced from 1.5 to 0.5 mg/ml to diminish
the severity of ulceration around the injection sites. Sec-
ondly, B. pertussis administration as second adjuvant was
omitted to obtain a milder EAE in which patterns of EAE
reactivity can be associated with the presence of certain
mhc alleles and cytokine profiles.20,21
Clinical Diagnosis
The clinical course of EAE was recorded daily by a
trained observer using semiquantitative scoring: 0  no
650 ’t Hart et al
AJP August 1998, Vol. 153, No. 2
clinical signs; 0.5  apathy, loss of appetite, altered
walking pattern without ataxia; 1  lethargy and/or an-
orexia; 2  ataxia; 2.5  para- or monoparesis and/or
sensory loss and/or brain stem syndrome; 3  para- or
hemiplegia; 4  quadriplegia; 5  spontaneous death
attributable to EAE. The highest per-day scores were
averaged over 1 week. Moreover, each monkey was
weighed at least three times per week to obtain a more
objective score of the clinical wellbeing.
MRI
MRI was performed at the Bijvoet Center of Utrecht Uni-
versity, The Netherlands. For each monkey, T2- and T1-
weighted magnetic resonance (MR) images were re-
corded, the latter also with contrast enhancement after
intravenous injection of gadolinium-diethylenetriamine-
penta-acetic acid (DTPA) (triple dose). The time points
for performing MRI after immunization were chosen dur-
ing periods of clinically active EAE.
In Vivo MRI
In preparation for the experiment, the monkeys were
anesthetized with ketamine/Vetranquil (9/1 v/v). During
scanning, each monkey was placed on a 37°C water-
filled heating pad (Granulab International BV, Amersfoort,
The Netherlands) to prevent hypothermia. The head of
the monkey was fixed in a custom-built stereotactic ap-
paratus made of metal-free plastics to ensure reproduc-
ible positioning in the magnetic field and to minimize
movement artifacts. The stereotactic apparatus was
placed inside a saddle-type radiofrequency coil. MRI
was performed on a SISCO 200-MHz spectrometer (Var-
ian, Palo Alto, CA) equipped with an actively shielded
gradient (maximum gradient 3.2 G/cm, 33 cm inner
diameter).
Postmortem MRI
T2-weighted MR images were recorded from formalin-
fixed brains to enable the determination of the exact
localization of the lesions that were detected in vivo. In
both scannings the same orientation points were chosen
for slice localization (see below). Because movement
artifacts were absent and long acquisition times can be
used, images of very high contrast can be obtained.
Slice Orientation and Scanning Procedure
First, a sagittal scout scan was made. The posterior and
anterior positions of the corpus callosum were chosen as
orientation markers for precise localization of the slices
for the in vivo and postmortem MRI. A T2 (echotime (TE)/
repetition time (TR), 60/2500 ms)-weighted multislice
scan (20 slices of 1 mm thickness) was obtained followed
by a T1-weighted scan (TE/TR, 25/1000 ms) with the
same spatial prescription. Gadolinium-DTPA (Magnevist;
Schering AG, Berlin, Germany) was injected intrave-
nously (0.3 mmol/kg) and allowed to circulate for 10
minutes to ensure adequate distribution. Next, the T1-
weighted MRI was repeated to attain a postcontrast data
set. Each slice was recorded with a matrix of 256  128
data points and a field of view of 5  5 cm. The data set
was analyzed on an Apple Macintosh Performa 630 using
the public domain NIH Image program.
Table 1. Histopathology of EAE in Marmosets Induced With and Without Bordetella
Animal Bordetella*
Time
point†
Clinical
score‡ Inflammation§
Infiltrate
composition DEM¶
Lesion
activity
Brain lesion
topography
Spinal
cord**
EB  21 3.0  Ly, M  A Opt, Fo 
EC  13 3.0  Ly, M  A CSO, Opt 
ED  6 3.0  Ly, M / A CSO, CWM 
EE  13 3.0  Ly, M  I CSO, Opt 
EG  11 4.0  Gr, Ly, M  A CSO, Thal 
EH  76 1.0  Ly, M  A  I Opt, CC,
CI, CSO

EI  35 2.0  Ly, M  A  I Opt, CC,
CI, CSO,
Thal

EJ  35 2.5 / Ly, M  A  I CC, Cer,
Med Obl

EK  24 2.5  Ly, M, Gr  I CC, CSO 
GY  12 2.5  Ly, M  A  I Opt, CC,
CI, CSO,
Thal

Ly, lymphocytes; M, macrophages; Gr, granulocytes; Opt, optic system; Fo, fornix; CSO, centrum semiovale (periventricular white matter); CWM,
cerebellar white matter; Thal, thalamus; CC, corpus callosum; CI, capsula interna; Med Obl, medulla oblongata; Cer, cerebellum.
*, with Bordetella; , without Bordetella.
†Time point (weeks after immunization) at which each animal was sacrificed.
‡Clinical score at time of sacrifice.
§0, no inflammation; , rare (1 to 3 perivascular cuffs/section); , moderate numbers (3 to 10) of perivascular cuffs/section; , widespread
perivascular cuffing and parenchymal infiltration.
¶Demyelination: /, single demyelinated fibers; , perivenous demyelination; , perivenous demyelination and some confluent plaques; ,
multiple confluent plaques.
A, active lesions; I, inactive lesions (, less than; , more than).
**, no involvement; , limited involvement; , moderate involvement; , extensive involvement.
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Figure 1. Course of EAE in marmosets. Six male marmosets were immunized with human myelin in complete adjuvant containing 1 mg/ml sonicated
Mycobacteria. For each individual monkey, the mean clinical scores (see Materials and Methods) recorded in a week are given (A). The body weight, which serves
as a surrogate disease marker, was measured at least twice weekly. For normalization, the body weights have been expressed as percentages of the measured
weights at the start of the study (B).
Figure 2. MRI of monkey EI 34 weeks after induction of EAE. a and b: Two slices of postmortem T2-weighted MRI in the axial direction. Lesions are indicated
with capitals in the figure. c and d: The corresponding slices in T2-weighted images, recorded 2 hours before sacrifice of the same monkey. e and f: The same
slices in T1-weighted images, recorded 2 hours before sacrifice of the same monkey. Contrast enhancement by extravasation of gadolinium is apparent in two
regions, I and C/D. In the in vivo T2-weighted images, ventricles and lesions are visible as the most hyperintense regions, whereas the most hypointense regions
represent the white matter. The hyperintensity of lesion I (periventricular localization) seen in the T2 in vivo MRI (c) probably results from edema. Lesion I is much
smaller in the postmortem MRI, probably because the formalin fixation changes the distribution of water in the parenchyma. Because of the absence of breathing
artifacts and longer scanning times, postmortem images have a higher resolution in which lesions are visible as sharply demarcated hyperintense regions. As an
example, in the postmortem T2 (d) and the T1 Gd-DTPA-enhanced MRI (f), a single hyperintense area (C/D) is present, which in the postmortem MRI (b) proves
to be two separate lesions, of which one is located in the gray matter (C) and one in the white matter (D).
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The T1-weighted MR images had an unexpected gray-
white matter contrast. In images recorded with the NMR
machines that are now used in clinical settings, which are
1.5 Tesla or less, a contrast conversion of the white and
gray matter is normally seen on T1-weighted versus T2-
weighted images. In T1-weighted images the NMR signal
of the white matter is hyperintense in comparison with
that of the gray matter, whereas in T2-weighted images
the white matter signal is hypointense compared with that
of the gray matter. In both the T1- and T2-weighted
images recorded on our 4.7-Tesla machine, white matter
is hypointense as compared with gray matter, and lesions
are visible as hyperintensities. This is not a unique feature
of the marmoset brain, given that it was also observed in
cat brains (unpublished observation). The most likely
explanation for this discrepancy is that with the high
magnetic field used, T1 values of gray and white matter
converge, whereas T2 values are unaffected by the
strength of the field. In our T1-weighted images, the
intensities of white and gray matter are most likely deter-
mined by the longer T2 value of gray matter and the
different proton densities of both tissues. This phenome-
non did not affect the detection of gadolinium enhance-
ment, because even long TR/short TE images (“proton-
density” weighted) contrast enhancement can be
observed.22
Histopathology Analysis
The brain and spinal cord of sacrificed monkeys were
excised and fixed in toto for 3 days in 4% buffered for-
malin and subsequently stored at 4°C in phosphate-buff-
ered saline, pH 7.4, containing sodium azide until analy-
sis. In some experiments the fresh brain hemispheres
were separated with a surgical blade, after which one
hemisphere was fixed in buffered formalin and the other
snap frozen in liquid nitrogen for immunohistological
analysis. The analysis of the frozen brains has been
published separately.23 Formalin-fixed brains were em-
bedded in paraffin. For the exact localization of lesions
that were MRI detectable in vivo, use was made of the
postmortem images. Because high-contrast images were
made in the coronal and axial directions using the same
orientation parameters as for the in vivo images, this en-
abled an accurate three-dimensional positioning of each
lesion. From this material, coronal sections with a thick-
ness of 3 to 5 m were cut.
The extent of inflammation, demyelination, and axonal
pathology was evaluated on tissue sections stained for
hematoxylin and eosin to visualize infiltrated cells, with
Klu¨ver Barrera stain (Luxol Fast Blue (LFB) combined
with periodic acid-Schiff (PAS)) for staining myelin and
myelin degradation products and with Bielschowsky sil-
ver impregnation for staining axons. Immunocytochemis-
try was performed with a biotin-avidin system as de-
scribed earlier.24 T cells were stained with anti-human
CD3 antibodies (Dakopatts, Glostrup, Denmark). Astro-
cytes were stained with polyclonal anti-glial fibrillary
acidic protein (Dakopatts). Macrophages were detected
by staining with the antibodies 27E10 and MRP14, which
are both commercially available from BMA Biomedicals
(Augst, Switzerland).25 Myelin and oligodendrocytes
were stained with antibodies recognizing 2	-3	-cyclic nu-
cleotide-3	-phosphodiesterase (CNP; Affinity Research,
Nottingham, UK), proteolipid protein (PLP) and myelin
oligodendrocyte glycoprotein (MOG) which were kindly
provided by Dr. S. Piddlesden (University of Cardiff, UK).
Immunoglobulin (Ig) depositions in the lesions were de-
tected using biotinylated anti-(human) Ig (Amersham,
Buckinghamshire, UK) as a primary antibody. Deposi-
tions of complement factor C9 were detected by a poly-
clonal antibody as described earlier.26
Lesional Staging
The maturation stage of a certain lesion was assessed
using previously published criteria for the classification of
MS lesions.27 In this classification scheme, lesions are
staged as follows: 1) early active lesions, presence of
LFB and MOG myelin degradation products in macro-
phages and/or the presence of macrophages stained for
macrophage antigen MRP14; 2) late active lesions, pres-
ence of myelin degradation products LFB and PLP but
not MOG in macrophages and/or the presence of mac-
rophages stained for macrophage antigens by 27E10 but
not MRP14; 3) inactive lesions, presence of PAS-positive
myelin degradation products but without LFB, PLP, or
MOG degradation products in macrophages; and 4) re-
myelinated lesions, presence of thin LFB-positive myelin.
Ethics
According to Dutch law on animal experimentation, the
experimental procedures of this study have been re-
viewed and approved by the Institute’s Animal Care and
Use Committee.
Results
In a first set of experiments, the originally documented
EAE model in marmoset monkeys18,19 was reproduced,
namely by immunization with human myelin in complete
adjuvant (with 3 mg M. tuberculosis per ml oil) and addi-
tionally intravenous administration of B. pertussis. As de-
scribed in the original reports, this procedure induced a
severe relapsing-remitting EAE. In our experience, how-
ever, the high Mycobacterium dose in the inoculum was
found to cause large ulcerative skin lesions at the injec-
tion sites. This not only meant discomfort for the monkeys
but also obscured early symptoms of neurological disor-
der in the lower part of the body. Furthermore, histopatho-
logical examination of CNS lesions showed that selective
demyelination occurred only in small perivenous lesions.
In the larger demyelinated lesions that were found around
the ventricles, but only in one of the five monkeys (Table
1), the axons were completely disrupted, suggesting that
the lesions were formed by a destructive inflammatory
process rather than by selective demyelination. For these
reasons we chose to further investigate EAE induced
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Figure 3. Correlation of T2-weighted MRI and histopathology. a and b: Two consecutive slices (coronal direction) of postmortem T2-weighted MRI of monkey EI. Klu¨ver
Barrera staining of the indicated regions H, K, I, and J are depicted in c to f (magnification, 366), showing that these are demyelinated lesions. c: The periventricular
lesion K, which is visible in both MR images, is an inactive demyelinated lesion showing signs of remyelination (see also Figure 5). d: Lesion I proved to be an early active
periventricular lesion (see also Figure 4 and Table 5) showing strong gadolinium enhancement (see Figure 2, e and f). e: Region H is an inactive lesion in the corpus
callosum, showing strong remyelination (arrow; see also Figure 5) in the upper part. The remyelinated and the nonremyelinated areas are visible in the T2-weighted MRI.
f: Region J is a chronic lesion of which the upper part showed gadolinium enhancement (see also Table 5).
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without administration of B. pertussis and using a reduced
Mycobacterium dose in the inoculum.
Clinical Expression of EAE
The clinical course of EAE was monitored using semi-
quantitative criteria (Figure 1a) and body weight mea-
surement as a surrogate disease parameter (Figure 1b).
All six monkeys developed a protracted form of EAE, but
substantial interindividual variation of disease courses
was observed. Monkey EH experienced several relatively
mild attacks, maximally reaching score 2.0 (ataxia), with
episodes of complete remission in between. This monkey
went into remission in the 49th week and remained free of
clinical signs up to week 76, when it was sacrificed for
pathological examination. In the five other monkeys (EI,
EJ, EK, EL, and GY), disease episodes of higher severity
alternated with episodes of incomplete remission, as was
particularly apparent from body weight measurements
(Figure 1b). In the advanced stages of EAE, clinical re-
mission in these monkeys was incomplete. Clinical signs
progressed to paraparesis (EI) and hemiplegia (EJ) or
paraplegia (EK, EL, and GY). Monkey EI was sacrificed
after a long period of chronic ataxia, monkey EJ with one
paralyzed leg and monkeys GY, EK, and EL with both
legs paralyzed. Importantly, none of the monkeys in this
experimental group died spontaneously.
MRI Analysis of EAE
In Vivo MRI
To visualize abnormalities in the brain white matter, T1-
and T2-weighted MR data sets were recorded during
episodes of active EAE. The first MR images were made
of all monkeys in the 17th week after immunization. At that
stage, regions with hyperintense signal intensity were
found around the ventricles on T2-weighted images.
Comparison with the T1-weighted images at that stage
with those recorded before EAE induction, showed that
the ventricles themselves were not enlarged. This obser-
vation points to periventricular edema (not shown). MRI
recorded at later disease stages showed a number of
circumscribed hyperintense regions within white matter
tracts such as the corpus callosum, but also in cerebral
gray matter (Figure 2, c and d).
Postmortem MRI
To assess the total lesion load in the brain, a T2-
weighted data set from all fixed brains was attained.
These postmortem MR images were compared with the
data from in vivo MR images, which were recorded 1 hour
before the monkey was sacrificed. Because of the ab-
sence of movement artifacts, the postmortem images
showed very high quality and contrast (Figure 2, a and b).
As reported previously, the contrast in T2-weighted MR
images of brain tissue before and after 6 weeks of fixation
in buffered formalin is comparable.28,29 In accordance
with this, all hyperintensities that were detectable in vivo
(Figure 2, c and d), were found in the postmortem images
(Figure 2, a and b). Using the combined data from MR
images made in the coronal (Figure 3, a and b) and axial
(Figure 2, a and b) directions, the exact localization of
each individual lesion in the fixed brain could be deter-
mined.
Histopathology
Pathological investigation of animals with EAE induced
without usage of Bordetella revealed the presence of
inflammatory lesions with predilection sites in the cere-
bral white matter and spinal cord (Table 1). Except for
some perivascular lesions, the cerebellum and medulla
oblongata in these animals were practically devoid of
inflammation. The cerebral lesions contained lympho-
cytes and macrophages, whereas accompanying gran-
ulocytes were sparsely found in some infiltrates in the
brain of animal EK. In general, the demyelination in these
animals led to the formation of large confluent plaques,
which were visualized by Klu¨ver Barrera stain (Figure 3, c
to f) or immunocytochemical staining for the myelin pro-
teins PLP (Figures 4e and 5a), CNP, and MOG. The CNS
of animals EH, EJ, and EK also contained, in addition to
the plaques, a large number of small demyelinated
perivascular lesions. Staining by Bielschowsky impreg-
nation revealed axonal reduction in active demyelinating
plaques which, because almost no spheroids were
present, occurred because of edema and the infiltration
of large numbers of inflammatory cells (Figures 4h and
5e). In most older inactive plaques, axons were very well
preserved. In a small minority of plaques, however, a
highly reduced axonal density was seen (Table 2).
Based on the presence of inflammatory T cells (Figure
4c) and LFB- and PAS-positive degradation products in
phagocytic macrophages, as well as on astrocytic scar
formation, we concluded that in all animals, active as well
as inactive lesions were present (Tables 1 and 2). In
addition to the standard histopathology, a fine character-
ization of each lesion was made by analyzing the pres-
ence of certain macrophage subpopulations by staining
Figure 4. Immunopathology of active lesions in monkey EI. a: Staining of regions I and J for macrophage marker 27E10 (magnification, 34). Note that lesion
I (see also Figures 2 and 3) shows 27E10 reactivity close to the lateral ventricle but also deeper in the parenchyma. b: Higher-magnification (335) 27E10-positive
macrophages in lesion J. c: Staining of CD3ve cells in lesion I, indicating strong T-cell infiltration (magnification, 335). d: MRP-14-positive macrophages in
lesion I (magnification, 990). e: Staining of lesion J with in situ hybridization for PLP mRNA combined with immunocytochemistry for PLP. The edge of this
lesion shows the presence of macrophages containing PLP degradation products (arrowheads). Outside the lesion, in between the myelin (red), PLP
mRNA-positive oligodendrocytes (brown; arrows) are found. In the lesion itself some weakly stained remaining oligodendrocytes (arrows) are present
(magnification, 388). f: PLP staining of lesion I showing the presence of macrophages with PLP degradation products (magnification, 684). g: The presence
of MOG degradation products in macrophages in lesion I (magnification, 792). h: Bielschowsky silver impregnation for axons showing the edge of lesion
J. Inside the lesion, likely because of edema, the density of axons is lower as in the surrounding tissue (magnification, 161). Active demyelination in lesion I
might occur through an antibody- and complement-mediated mechanism. i: Deposition of Igs on bundles of myelin (arrow). The punctate staining indicates that
these myelin sheaths undergo degradation (magnification, 308). j: The staining for complement C9 reveals that the same bundles that are opsonized with Igs
also show deposition of C9 (magnification, 308).
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with the antibodies 27E10 and MRP14 and for intracellu-
lar presence of MOG and PLP protein degradation prod-
ucts. Inactive demyelinated lesions, showing absence of
LFB-positive material (Figure 5d) and only a moderate
amount of PAS-positive myelin breakdown products in
macrophages, also lacked staining with the macrophage
markers 27E10 and MRP14. The macrophages in these
lesions did not contain detectable amounts of MOG and
PLP. In contrast, active lesions contained many macro-
phages that stained positively with the antibody 27E10
(Figure 4, a and b) and contained LFB-positive material.
Macrophages expressing MRP14 (Figure 4d) and con-
taining the myelin degradation product MOG (Figure 4g)
were found only in some of the active lesions. The MOG
and PLP staining showed that all KLB- and 27E10-positive
lesions contained macrophages with intracellular inclusions
of PLP-positive degradation products (Figure 4f).
Because Ig- and complement-mediated mechanisms
are involved in myelin degradation in rodent EAE models,
and possibly also in MS,25,30 we have investigated the
presence of Ig and complement factor C9 in demyeli-
nated lesions. Ig deposition was found in a variety of
lesions ranging from inactive to active. In some of the
early active lesions, such as lesions D and I of animal EI,
punctate Ig deposition was found on myelin sheaths,
pointing to active myelin destruction (Figure 4i). Although
Ig molecules were present in both active and inactive
lesions, complement factor C9 could only be demon-
strated in the (early active) lesions in a similar distribution
as that of the punctate Ig deposition described above
(Figure 4j).
Besides active and inactive demyelinated lesions, re-
myelinated plaques were also found (Figure 5). Remyeli-
nated lesions, or shadow plaques due to the presence of
very thin LFB-positive myelin sheaths (Figure 3e and 5c),
showed strong staining of myelin and oligodendrocytes
by immunocytochemistry for CNP (Figure 5h). Remyeli-
nating activity was found not only in inactive lesions, but
also in early and late actively demyelinating lesions. In
situ hybridization for PLP mRNA revealed that areas of
active remyelination contained high numbers of oligoden-
drocytes that expressed PLP mRNA in their cytoplasm
(Figure 5, a, b, f, and g).
MRI-Pathology Correlation
High-contrast T2-weighted MR images of fixed brains
were recorded using the same parameters for slice ori-
entation as used for in vivo MRI. The postmortem images
were used to study the possible MRI-pathology correla-
tion of lesions.
In animals EI and GY, virtually all confluent lesions that
could be detected by histopathology were also visible in
the postmortem T2-weighted MRI. However, no clearly
diverse T2 signal intensities could be detected between
lesions with different histopathological aspects (Figure 3
and Table 3). We are currently planning quantitative T2
measurements to investigate this issue in more detail. In
animals EH, EJ, and EK, the correlation between pathol-
ogy and MRI was more difficult. Many of the very small
perivascular or periventricular lesions could not be re-
trieved in the corresponding MRI. Moreover, the majority
of the small hyperintense regions in the T2-weighted MR
images, eg, those in the corpus callosum of animal EK,
were not found at the same place by pathological inves-
tigation. However, the total number of lesions that were
found with pathology and MRI in the corresponding areas
was similar (Table 4). This suggests that the discrepancy
in correlation of pathology and MRI has a technical rea-
son, such as small differences in the plane of sectioning,
rather than that these lesions differ in T2 characteristics
from larger “pathological” lesions that could be traced
easily in MRI. Little is known on the MRI appearance of
remyelinated lesions. Our present data show that, as
predicted by Barkhof,31 the shadow plaque K (Figures 3c
Figure 5. Remyelination and inactive lesions. a: Remyelination in lesion H of monkey EI (compare Figure 3, b and e), shown by in situ hybridization for PLP
mRNA combined with immunocytochemistry for PLP. Small black dots indicate PLP mRNA-positive oligodendrocytes. Whereas the lower side of the lesion
(indicated by b) shows the absence of oligodendrocytes and myelin, the upper side (indicated by a) shows high numbers of oligodendrocytes, indicating active
remyelination. b: Higher magnification (61) of the remyelination in the upper part of lesion H (compare position of asterisk in a and b). Arrows point at PLP
mRNA-positive oligodendrocytes that are present in high numbers in the remyelinating area. The small dots (arrowheads) in between the oligodendrocytes are
newly formed myelin sheaths staining positively for PLP protein (magnification,190). c and d: Klu¨ver Barrera stain for myelin of lesion H. In c, the remyelinating
part of lesion H is shown (the letter “a” in the figure corresponds with area “a” in part a). Arrowheads indicate newly formed LFB-positive fibers in this area
(magnification,300). In d, the lower part of lesion H is depicted, corresponding with area b in part a. Unlike in the upper part, no LFB-positive fibers are present,
indicating the lack of remyelination in this inactive lesion (magnification, 300). f: In situ hybridization for PLP mRNA combined with immunocytochemistry for
PLP protein of lesion K (see also Figure 3, a to c). Black dots indicate high numbers of PLP mRNA-positive oligodendrocytes in this remyelinating lesion
(magnification, 61). g: Higher magnification of lesion K showing the PLP mRNA-positive oligodedrocytes (magnification, 238). h: Immunocytochemical
staining for CNP shows strong staining of myelin fibers (arrowheads) and oligodendrocytes (arrows) in lesion K (magnification, 350).
Table 2. Characteristics of Active and Inactive Demyelinated Lesions
Type of
lesion T cells B cells M
Myelin breakdown Astrocytes/
gliosis
Axonal
densityLFB PAS
EA  /    Prot astr Reduced*
LA  /    Fibr gliosis Reduced*
IN v / v  v Fibr gliosis Normal†
M, macrophages; EA, early active; LA, late active; IN, inactive; , high number of cells; /, some cells; , no cells; v, variable numbers of cells
in different lesions; prot astr, protoplasmic (activated) astrocytes; fibr, fibrillary.
*Lower axonal density due to edema and infiltration of inflammatory cells rather than destruction of axons.
†Most lesions showed little/no axonal loss; a small number of lesions showed axonal loss.
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and 5f) appears as a hyperintense region in T2-weighted
MRI (Figure 3a).
Of particular interest is the correlation between the
activity characterization of a given lesion based on his-
topathological and MRI criteria. Ten out of 14 lesions that
showed early demyelinating activity, ie, MOG-positive
myelin breakdown products in macrophages and/or
presence of MRP14-positive macrophages, displayed
gadolinium enhancement (Table 3). A false negative
score may occur when the amount of extravasated gad-
olinium is too low to cause a detectable change of the
T1-weighted NMR signal intensity (partial volume effect).
This may take place when extravasation occurs only in
peripheral parts of a lesion. Hence, lesions that were
peripheral parts of a gadolinium-enhancing lesion were
analyzed as a separate group within the pathologically
defined demyelinating lesions (Table 3). With this precau-
tion in mind, all gadolinium-positive lesions could be
classified as early demyelinating lesions, containing high
numbers of MOG-positive macrophages (Tables 3 and
5). Gadolinium-negative lesions that are closely associ-
ated with gadolinium-positive lesions were shown to be
early active lesions too. However, gadolinium-negative
lesions that were not associated with gadolinium-positive
lesions contained PLP-positive or 27E10-positive macro-
phages, but MOG- or MRP14-positive macrophages
were absent, and these were, therefore, classified as late
active (Tables 3 and 5). None of the pathologically de-
fined inactive lesions (n  58) displayed gadolinium en-
hancement of the T1-weighted NMR signal intensity (Ta-
ble 5).
Gadolinium enhancement of T1-weighted images de-
tects extravasation of the paramagnetic molecules
through a disrupted BBB. As a confirmatory histological
marker for BBB leakage, the MRI-detectable lesions were
stained for the presence of albumin. Strong albumin im-
munoreactivity was found both in gadolinium-enhancing
as well as gadolinium-nonenhancing early and late de-
myelinating lesions, suggesting that in the nonenhancing
lesions, BBB leakage may have taken place before the
Table 3. Gadolinium Extravasation and Albumin Leakage in Early and Late Active Demyelinated Lesions in Monkeys EI and GY
Lesion* Gd-DTPA Albumin KLB PLP MOG 27E10 MRP14
Lesion
activity
Gadolinium-enhancing lesions
E1(GY)       ND EA
E2(GY) /      ND EA
G(GY) /      ND EA
J(GY)       ND EA
P(GY)       ND EA
O(GY) /    ND  ND EA
C(EI)        EA
D(EI)        EA
I(EI)        EA
J(EI) /    /  / EA/LA
Lesions associated with gadolinium-enhancing lesions
H(GY)       ND EA
I(GY)       ND EA
M(GY)       ND EA
N(GY)       ND EA
Lesions not associated with gadolinium-enhancing lesions
K(GY)     ND  ND EA/LA
L(GY)     ND  ND LA
F1(GY)  ND   / / ND LA
F2(GY)  ND   / / ND LA
Q(GY)       ND LA
*Lesion: name of lesion; the name of the monkey is given in parentheses. , no reactivity; /, some reactivity or reactivity in part of the lesion; ,
reactivity throughout the lesions; , strong reactivity/high numbers of immunoreactive cells. EA, early active lesion; LA, late active lesion; ND, not
done.
Table 4. Comparison of the Numbers of Lesions Detected with Pathology and MRI
Animal
Total lesions
in pathology
Total lesions
in T2MRI
Dem. lesions
in pathology*
DEM/REM activity
EA LA IN REM
EI 18 20 13 (12) 4 0 9 7
EH 56† 65 22‡ (4) 0 3 19 4
EJ 31† 38 17‡ (8) 0 2 15 3
EK 40†§ 35 10 (6) 0 0 10 3
GY 25 26 20 (16) 11 4 5 5
EA, early active; LA, late active; IN, inactive; REM, remyelinating; DEM, demyelinating.
*Demyelinated lesions; numbers in parentheses indicate numbers of demyelinated lesions that are detectable in T2 MRI and of which a
corresponding lesion in pathology was found.
†Contained many small perivascular lesions.
‡Contained a number of small lesions with perivascular demyelination.
§Contained a number of shadow plaques, which were not further characterized with histopathology.
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MR images were made. In (nonenhancing) inactive le-
sions, only weak albumin immunoreactivity was found
(data not shown).
Discussion
The aim of this study was to analyze histopathological
characteristics of MRI-detectable lesions and to evaluate
sensitivity and specificity of the most commonly used MRI
acquisitions in a valid animal model of MS. For this pur-
pose, chronic EAE was induced in a panel of randomly
selected marmosets. At different time points during the
course of EAE, MR images were made, after which ani-
mals were sacrificed for histopathological examination.
The current histopathological characterization of de-
myelinating activity in lesions is based on the presence of
material positive for LFB, PAS, or Oil Red O (for neutral
lipids) in phagocytic macrophages. However, especially
PAS and Oil Red O positivity in macrophages can be
found for more than 6 months after a new demyelinating
lesion has developed, which implies that the presence of
PAS- and Oil Red O-positive material may not always
reflect ongoing demyelination.25 Recent studies have
shown that the presence of myelin protein breakdown
products, such as MOG, myelin basic protein, or PLP, in
macrophages gives a more accurate characterization of
the stage of demyelinating lesions.27,32 Early stages of
demyelination can also be distinguished by the expres-
sion of the macrophage activation markers MRP14 or
27E10.27 By combination of the classical and the new
markers, a stringent stage characterization of demyeli-
nating lesions can be made. By using these criteria for
lesional staging, we were able to demonstrate that es-
sentially all types of lesions present in MS brain (perivas-
cular, paraventricular, active, and inactive demyelinating
and remyelinating) are also present in EAE-affected mar-
moset brains. We conclude therefore that in the present
model the main characteristics of MS pathology can be
found. The fact that the same set of markers can be used
for the pathological characterization of the lesions in the
CNS of MS patients as in the marmoset model is of great
value for extrapolation of experimental and patient data.
This report documents the correlation of radiological
(MRI) and histopathological characteristics of the CNS
white matter lesions in the marmoset EAE model. Normal
brain tissue is highly organized, determining the typical
MR relaxation times. The standard T2-weighted se-
quences are very sensitive to structure disturbances rep-
resenting all stages of lesion formation as hyperintense
regions. Therefore, in human brain, T2-weighted MR im-
ages are very suitable for assessing the spatial lesion
distribution, but because of the inherent low specificity
the images provide only little information on the nature of
lesions.29 Our data show that the shape and localization
of the MRI-detectable lesions in the brain of marmosets
developing EAE resembles the situation in the CNS of MS
patients. In accordance with data from others, the T2-
weighted MR images made of formalin-fixed brains do
not essentially differ from the T2-weighted images made
in vivo.28,31 We have used high-contrast postmortem MRI
for exact three-dimensional localization of lesions of in-
terest for further characterization with histology. In the
pathology and MRI analysis of marmoset brains, similar
numbers of lesions were counted, indicating that, as in
humans, T2-weighted MRI can be used to determine the
total lesion load.
Extravasation of intravenously injected gadolinium is a
radiological criterion for active lesions that can be seen
as focal enhancement of T1-weighted signal intensity. By
using a whole set of histopathological parameters, we
were able to demonstrate 1) that all early active lesions
display gadolinium enhancement in T1-weighted MRI
and 2) that, with the exception of one lesion (K), all
nonenhancing lesions could be characterized as inactive
or late active lesions. A discrepancy exists in a subgroup
of pathologically defined active lesions, which are lo-
cated very close to gadolinium-enhancing lesions in ad-
jacent scans, but which displayed no detectable extrav-
asation of gadolinium. The discrepancy between the
histological and radiological markers for BBB leakage
may have a technical reason, ie, that gadolinium extrav-
asation in only a small part of a lesion may yield an
insufficient concentration of the paramagnetic molecule
to exert a visible effect on the T1-weighted NMR signal
intensity of the whole lesion (partial volume effect). An-
other explanation for the detection of albumin and the
absence of gadolinium is that leakage of molecules such
as albumin and Igs from serum to the brain is a continu-
ous phenomenon, whereas gadolinium-DTPA is given in
a single injection and therefore may reach concentrations
too low to detect in the late active lesions.
As indicated in Table 5, many lesions appear as hy-
perintensities in our in vivo T1-weighted images. Given
the virtual lack of axon pathology, structures such as
“black holes” could not be expected. Moreover, no ap-
parent correlation with certain stages of lesion differenti-
ation could be found. We have no explanation for the
observed phenomenon, and comparable to the different
T1 values of gray and white matter (see Slice Orientation
and Scanning Procedure, in Materials and Methods), we
Table 5. T1 and T2 Characteristics of the Different Types of Lesions
Lesion
MRI characteristics
T2 (postmortem) T1 T1-Gd-DTPA
Early active Hyperintense Hyperintense  isointense Enhancing
Late active Hyperintense Isointense  hyperintense Nonenhancing
Inactive Hyperintense Isointense  hyperintense Nonenhancing
Remyelinating Hyperintense Isointense  hyperintense Nonenhancing
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like to attribute it to the high magnetic field. Experiments
are now in preparation to quantitate NMR signal intensi-
ties of individual lesions to correlate these data with
quantitative immunohistochemical criteria of demyelina-
tion, remyelination, and axonal loss. We are also investi-
gating whether administration of a higher Gadolinium
dosage than the currently used triple dose may increase
the numbers of detectable lesions with BBB leakage or
demyelinating activity.
In summary, the new marmoset EAE model is a valid
experimental model for human MS in which lesion forma-
tion can be investigated with MRI and pathology. In view
of the central role of autoimmune factors in the etiopatho-
genesis of MS, the high similarity of the human and
marmoset immune systems is of great importance. In this
respect, a high degree of homology in the genes encod-
ing for T-cell receptor subunits15 and major histocompat-
ibility complex molecules (Ref. 16 and S.G. Antunes et al,
submitted), as well as significant immunological cross-
reactivity of lymphocyte surface markers and cytokines,
have been documented.11–13,23 These collective data
make this model a unique tool for basic research in MS
and EAE and for preclinical evaluation of new therapies
for MS.
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